If Channel Inhibition - Ivabradine for the Treatment of Heart Failure
The novel first-in-class If channel antagonist, Ivabradine, is effective in improving clinical outcomes and functional capacity, in patients with HF, as well as demonstrating useful anti-anginal and protective anti-ischaemic effects. It can help improve heart rate control and can be usefully co-admi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Barcaray International
2019-01-01
|
| Series: | International Cardiovascular Forum Journal |
| Subjects: | |
| Online Access: | https://icfjournal.org/index.php/icfj/article/view/599/pdf |
| id |
doaj-6be4d0f4f271424c8a50e2f1d042b26e |
|---|---|
| record_format |
Article |
| spelling |
doaj-6be4d0f4f271424c8a50e2f1d042b26e2020-11-25T03:26:20ZengBarcaray InternationalInternational Cardiovascular Forum Journal2410-26362409-34242019-01-01172628https://doi.org/10.17987/icfj.v17i0.599If Channel Inhibition - Ivabradine for the Treatment of Heart FailureGiuseppe MC Rosano0Cristiana Vitale1Centre for Clinical & Basic Research IRCCS San Raffaele Pisana, via della Pisana, 235, 00163 Rome, ItalyDepartment of Medical Sciences, IRCCS San Raffaele Pisana, Rome, ItalyThe novel first-in-class If channel antagonist, Ivabradine, is effective in improving clinical outcomes and functional capacity, in patients with HF, as well as demonstrating useful anti-anginal and protective anti-ischaemic effects. It can help improve heart rate control and can be usefully co-administered with beta blockers on HFrEF patients with residually elevated resting sinus rhythm heart rate. We review the clinical trial evidence for the benefits of Ivabradine in the treatment of heart failure.https://icfjournal.org/index.php/icfj/article/view/599/pdfheart failureivabradineclinical trial |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Giuseppe MC Rosano Cristiana Vitale |
| spellingShingle |
Giuseppe MC Rosano Cristiana Vitale If Channel Inhibition - Ivabradine for the Treatment of Heart Failure International Cardiovascular Forum Journal heart failure ivabradine clinical trial |
| author_facet |
Giuseppe MC Rosano Cristiana Vitale |
| author_sort |
Giuseppe MC Rosano |
| title |
If Channel Inhibition - Ivabradine for the Treatment of Heart Failure |
| title_short |
If Channel Inhibition - Ivabradine for the Treatment of Heart Failure |
| title_full |
If Channel Inhibition - Ivabradine for the Treatment of Heart Failure |
| title_fullStr |
If Channel Inhibition - Ivabradine for the Treatment of Heart Failure |
| title_full_unstemmed |
If Channel Inhibition - Ivabradine for the Treatment of Heart Failure |
| title_sort |
if channel inhibition - ivabradine for the treatment of heart failure |
| publisher |
Barcaray International |
| series |
International Cardiovascular Forum Journal |
| issn |
2410-2636 2409-3424 |
| publishDate |
2019-01-01 |
| description |
The novel first-in-class If channel antagonist, Ivabradine, is effective in improving clinical outcomes and functional capacity, in patients with HF, as well as demonstrating useful anti-anginal and protective anti-ischaemic effects. It can help improve heart rate control and can be usefully co-administered with beta blockers on HFrEF patients with residually elevated resting sinus rhythm heart rate. We review the clinical trial evidence for the benefits of Ivabradine in the treatment of heart failure. |
| topic |
heart failure ivabradine clinical trial |
| url |
https://icfjournal.org/index.php/icfj/article/view/599/pdf |
| work_keys_str_mv |
AT giuseppemcrosano ifchannelinhibitionivabradineforthetreatmentofheartfailure AT cristianavitale ifchannelinhibitionivabradineforthetreatmentofheartfailure |
| _version_ |
1724593363370377216 |